Ultragenyx Pharmaceutical Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
RARE$15.43-0.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ULTRAGENYX PHARMACEUTICAL INC. | |||
| Date: November 5, 2024 | By: | /s/ Emil D. Kakkis | |
|---|---|---|---|
| Emil D. Kakkis, M.D., Ph.D. | |||
| President and Chief Executive Officer and Director(Principal Executive Officer) | |||
| Date: November 5, 2024 | By: | /s/ Howard Horn | |
| Howard Horn | |||
| Executive Vice President, Chief Financial Officer, Corporate Strategy(Principal Financial Officer) | |||
| Date: November 5, 2024 | By: | /s/ Theodore A. Huizenga | |
| Theodore A. Huizenga | |||
| Senior Vice President and Chief Accounting Officer(Principal Accounting Officer) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.